Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in transfusion-dependent lower-risk myelodysplastic syndrome after ESA failure
MOH_2019-11-07_007475Phase 3Recruiting
- Sponsor
- Geron Corporation
- Start
- Aug 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in myelodysplastic syndrome (MDS) comparing Imetelstat with Placebo (2 arms). Started Aug 2019; status: recruiting.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2019-11-07_007475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-07_007475.